Overall market sentiment has been high on Cytosorbents Corp (CTSO) stock lately. CTSO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Cytosorbents Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTSO!
Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends.
Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor.
InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon.
The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.
What's Happening With CTSO Stock Today?
Cytosorbents Corp (CTSO) stock is up 11.29% while the S&P 500 has fallen -1.06% as of 1:08 PM on Friday, Dec 30. CTSO is higher by $0.16 from the previous closing price of $1.40 on volume of 308,035 shares. Over the past year the S&P 500 is lower by -20.55% while CTSO has fallen -62.41%. CTSO lost -$0.95 per share in the over the last 12 months.
More About Cytosorbents Corp
CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.
Click Here to get the full Stock Report for Cytosorbents Corp stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
